

# **Policies and incentives for promoting innovation in antibiotic research**

**Elias Mossialos, Chantal M Morel, Suzanne Edwards,  
Julia Berenson, Marin Gemmill-Toyama, David Brogan**

This study was commissioned and financed by the  
Swedish Government

European

**Observatory**

on Health Systems and Policies

# Contents

List of tables, figures and boxes	vii
List of abbreviations	xi
Glossary	xiii
Foreword	ixx
Acknowledgements	xxi
10 key messages	xxiii
<b>Introduction</b>	<b>1</b>
<b>Chapter 1 Background on antibiotics</b>	<b>9</b>
1.1 What are antibiotics?	9
1.2 Why antibiotics are important	10
1.3 Externalities of antibiotics and AR	11
<b>Chapter 2 Background on AR</b>	<b>15</b>
2.1 What is AR?	15
2.2 Severity of AR	16
2.2.1 AR trends in developed countries	16
2.2.2 AR trends in developing countries	20
2.3 Clinical and economic impact of AR	21
2.3.1 Clinical outcomes	21
2.3.2 Costs of resistance	23
<b>Chapter 3 Causes of AR</b>	<b>27</b>
3.1 Misuse of antibiotics	27
3.1.1 Physicians and health-care providers	28
3.1.2 Livestock and agriculture	31
3.2 Role of diagnostics in AR	32
3.3 Role of vaccines in AR	36
3.3.1 Examples from Europe	37
3.3.2 Examples from the United States	37
3.4 Lack of new antibiotics	37
3.4.1 The antibiotic market	38
3.4.2 Areas of unmet need	43
<b>Chapter 4 Reasons for limited innovation</b>	<b>49</b>
4.1 Antibiotic restrictions deter pharmaceutical investment in R&D	49
4.2 Challenges in the antibiotics market - NPV	50

4.3	Regulatory environment	53
4.4	Estimated cost of drug development	54
4.5	Scientific challenges	57
<b>Chapter 5 Health system responses to AR</b>		<b>59</b>
5.1	Examples from Europe	61
5.2	Examples from the United States	63
<b>Chapter 6 Analysis of opportunities and incentives to stimulate R&amp;D for antibiotics</b>		<b>67</b>
6.1	Push incentives	67
6.1.1	Increasing access to research	68
6.1.2	Scientific personnel	71
6.1.3	Direct funding of research	71
6.1.4	Translational research	77
6.1.5	Tax incentives	79
6.1.6	PDPs	83
6.2	Pull incentives	89
6.2.1	Monetary prizes	89
6.2.2	Advance market commitments	95
6.2.3	Patent buyout	100
6.3	Lego-regulatory mechanisms	100
6.3.1	Clinical trials	101
6.3.2	Intellectual property mechanisms	106
6.3.3	Expedited regulatory review	117
6.3.4	Pricing and reimbursement	121
6.3.5	Liability protection	126
6.3.6	Antitrust laws	127
6.3.7	<i>Sui generis</i> rights	127
6.4	Combined push-pull incentive models	128
6.4.1	Orphan drug designation	128
6.4.2	Call options for antibiotics model	129
<b>Chapter 7 Conclusions</b>		<b>137</b>
7.1	Rationale for intervention in the antibiotics market	137
7.2	Preserving the effective life of existing and new antibiotics	139
7.3	Key concepts in incentive design	141
7.4	Conclusions on individual incentives	147
7.4.1	Direct public subsidy for basic research	147
<b>Appendix A. EU Council conclusions on innovative incentives</b>		<b>159</b>
<b>Appendix B. US-EU joint declaration on creation of transatlantic taskforce on antimicrobial resistance</b>		<b>161</b>
<b>Appendix C. Global vaccine research</b>		<b>175</b>
<b>Appendix D. Possible funding mechanisms for a COA scheme</b>		<b>177</b>
<b>References</b>		<b>179</b>